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1. The Problem 
There has been a gradual but major change in oral contraception. The drive to 
reduce metabolic assault and unwanted side-effects has resulted in a trend toward 
formulations which are less contraceptive and more likely to be abortifacient. 
This has a broad range of moral consequences. 
There is not one formulation of the contraceptive-abortifacient pill but many 
varieties. In general, there are three actions involved: the effect on the cervix, on 
ovulation and on the lining of the uterus. 
The estrogen content is significant in suppressing ovulation. The lower the 
estrogen dose, the greater the likelihood that ovulation will not be suppressed. In 
the latter case the cervical and endometrial factors are more significant. In the 
various formulations it is not known how often that both ovulation is not 
suppressed and the cervical factor fails to block the passage of sperm and so 
allows fertilization followed by an endometrial effect causing loss of the zygote. 
However it is likely that that is sometimes the result of taking oral contraception 
and it is more likely in the circumstances of the newer formulations with their 
much lower estrogen content and reduced effect on ovulation. The likely induced 
loss rate of zygotes, though low, is of serious moral significance because it is 
human life that is at risk. 
The progesterone-only formulations are more likely to have this unfortunate 
abortifacient result than the combined estrogen-progestogen formulations. 
The "contraceptive pill" (meaning either the combined estrogen and 
progestogen preparations or the progestogen only preparations) ought not be 
regarded as contraceptive only. There is a significant chance of abortifacient 
effect which increases as the estrogen content diminishes. The increased 
likelihood of the various formulations being abortifacient changes the moral 
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evaluation of material cooperation by health professionals in regard to 
contraception. The grave matter of justice and respect for nascent human life 
arises. 
There is a need for clear teaching on contraceptive-abortifacients and the deceit 
involved, not only in order to address the matter of respect for human life but also 
the matter of the rights of women to know what they are doing to their own bodies 
and to the lives for whom their bodies are rendered hostile. Such a statement might 
also address the moral conclusions that flow from that information in regard to the 
practice of contraception and abortifacience and the issue of cooperation. 
Also to be considered are new birth control developments other than the 
estrogen-progestogen pill. The new preparations are nearly all primarily 
abortifacient although they are usually trialled, approved and/or marketed 
misleadingly as "contraceptive". 
2. The Distinction Between Contraception and Abortifacience 
For the purposes of this analysis which is concerned ultimately with some moral 
questions, the terms "abortifacient" and "contraceptive" are defined in the 
following way: 
A contraceptive effect occurs when the natural process of human generation 
originating in the marital act is prevented, by some form of deliberate intervention 
in the human body or in the act itself, from resulting in fertilization of an ovum by a 
sperm. 
An abortifacient effect occurs when intervention takes place of a kind which 
would be likely, if fertilization were to have occurred, to destroy the human 
zygote, embryo or fetus, to prevent its implantation, or to cause an implanted 
embryo or fetus to miscarry. The human zygote is the cell formed by the fusion of 
the two gametes ("Zygotum est cellula ona afusione duorum gametum"J). 
There is a distinct difference between the moral significance of a contraceptive 
effect and of an abortifacient effect. The fruit of human generation, from the first 
moment of its existence, that is to say from the moment the zygote is formed, 
demands the unconditional respect that is morally due to the human being in his 
bodily and spiritual totality. ("Quare fructus generationis humanae, inde a primo 
temporis momento quo exsistere incipit. hoc est a momento quo formatio zygoti 
inchoatur, absolutam illam exgit observantiam, quae ex lege morali homini debetur 
quoad totam suam rationem corpora/em atque spiritualem "2) 
There are at least twenty-four different formulations of the estrogen-
progestogen oral contraceptive in approved use in Australia3• They do not all have 
the same pharmacological action. It is not merely a question of being stronger or 
weaker doses of the same hormones, but different preparations with different 
effects. 
To clarify the matter, this section differentiates between each of the types of the 
pill in approved use in Australia and gives an account of the effects of each type in 
regard to the mechanism by which they prevent the development of pregnancy, so 
far as the specific pharmacological actions are known. In addition, some details of 
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new formulations which are currently being experimentally tried in Australia, but 
are not yet approved for general use, are also included. Finally, an opinion is 
offered in regard to moral issues arising from the blurring of the distinction 
between contraception and abortion that has occurred through the gradual 
development of contraceptives toward being more abortifacient than contraceptive. 
3. Combined Pills 
These are pills which have a combination of both estrogen and progestogen4. 
The estrogen in all the approved formulations available in Australia is 
ethinylestradiol with the daily dosage varying between 30 - 50 mcg5• The 
progestogen content however comes in several formulations: Levonorgestrel 
(150-250 mcg), Norethisterone (500-1000mcg) Ethynodiol diacetate (500-
lOOOmcg) and Desogestrel (l50mcg)6. The formulation and the dosage are both 
significant in relation to the action of the pills in regard to which of the three 
actions - the suppression of ovulation, the disruption of cervical mucus, or 
changes to the endometrium (causing loss of the zygote) - are likely to be factors 
preventing fertilization and/or the development of a pregnancy.? Further, the 
response to these agents varies from woman to woman and between cycles. As the 
woman's own hormonal levels fluctuate from cycle to cycle and different women 
have different hormonal levels, the action of these agents on the ovaries, cervix and 
endometrium varies.s 
The effect of the formulations is on the hypothalamus and/or the pituitary gland 
in the brain which produce the hormones which affect the reproductive cycle9. 
Some of the formulations work to suppress Follicle Stimulating Hormone (FSH) 
and Luteinizing Hormone (LH), some suppress only FSH production, and some 
simply disturb the FSH and LH cycle so that instead of the LH surge happening 
following a period of sustained FSH, there may be several LH pulses which do not 
coincide with follicle maturation. Some suppress only LH. Some formulations 
may simply disrupt the coincidence of the receptiveness of the endometrium to 
implantation, cervical mucus sperm penetrability and ovulation so that while these 
events' occur they do not happen with a timing that allows both fertilization and 
implantation to occur.IO 
Generally, if the formulation being used has a high estrogen content, then the 
likelihood is that ovulation will be suppressed and the matter of an abortifacient effect 
on the endometrium would not arise.11 In the formulations with a low estrogen 
content, ovulation would be less likely to be suppressed and the actions of the 
progestogen on the cervix and the endometrium become more significantl2. 
Generally, the higher and the more prolonged the dose of progestogen, the greater the 
disruption to the cervial mucus and the lower the chance of fertilization occurring and 
hence the lower the chance of an abortifacient effectl3. 
The type of progestogen formulation being used is also relevant Some have a 
slower more sustained absorption than others. Some are rapidly absorbed. Some 
have a shorter half-life than others. These differences are significant A sustained level 
of progestogen throughout the day is probably necessary to maintain disruption of 
the cervical mucus, thus maintaining a contraceptive effect. Whether it is necessary 
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for it to be sustained to maintain the effect on the endometrium or whether the 
endometrium would be sufficiently disrupted by daily peaks of progesterone is not 
clear. Peaks and troughs in the progesterone levels may cause the breakthrough 
bleeding seen in some women using the low dose oral contraceptive pill, indicating 
that the endometrium is disturbed 14. In that case the abortifacient effect on the 
endometrium, rather than the contraceptive effect achieved in the cervix, is more 
likely in formulations that do not provide a sustained level of the hormones 
throughout the day. An additional factor is that it appears that the ratio of&tradiol 
to Progesterone is significant in relation to the effect on the endometrium IS. 
In the event of low estrogen levels, ovulation occurring and unsustained 
progestogen levels, it is not clear from the literature which is the more likely to 
function adequately, the cervical mucus or the endometrium. Hence it is not 
possible to say definitely that there are circumstances with the combined pills in 
which the sperm penetrates the ovum and fertilization occurs, but the zygote is lost 
because of the damage to the endometrium. It may be the case that the disruption 
to cervical function is always relatively greater than the damage to the 
endometrium. However, it should be assumed that any damage to the 
endometrium is likely to increase the risk of zygote loss. The combined pill 
certainly causes atrophic changes to the endometrium which then becomes an 
unreceptive environment to the zygote. Second, there is a pregnancy rate in the 
actual clinical use of the combined pill indicating that the cervical effect is not 
always sufficient. For those reasons the possibility that the combined pill in some 
circumstances allows fertilization to occur while increasing the likelihood of 
implantation failure cannot be considered as improbable. That probability 
increases in the combined pills using lower estrogen doses. 
So far this discussion has presumed strict compliance in users in both taking the 
pill each day and taking it at the same time of day. Of course this often does not 
happen. Most of the pregnancies associated with pill usage are attributed to user 
error rather than method error. It can only be a matter of speculation as to which of 
the organs is the first to function when a pill is missed or delayed, the ovaries, the 
cervix or the endometrium. Hence it is not known how many missed pills actually 
result in fertilization and subsequent failure to implant. At a guess it d~ seem 
probable that the endometrium may be slower to return to function than the cervix 
and hence the abortifacient effect may be more likely}6 
Similarly, many drug interactions which reduce the efficacy of oral 
contraceptives resulting in pregnancy are knownl7• It is not known how often drug 
interaction would be sufficient to allow ovulation and sperm penetration, but 
would not be sufficient to prevent damage to the endometrium and hence an 
abortifacient effect18• 
There is some indication that there may be a prolonged effect of the oral 
contraceptives on both the endometrium and the cervix after a woman has ceased 
taking the pill. There may well be a greater likelihood of miscarriage in that period 
also as a result of some chromosomal abnormalities. 19 Professor Jerome Lejeune 
drew attention to the greater incidence of chromosomal abnormalities resulting in 
miscarriage, and thought that there was a greater incidence of Trisomy 21 (Down 
Syndrome) after the use of hormonal contraception.20 It is worth noting that the 
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consumer advice from the manufacturers cautions that pregnancy should be 
avoided in the first three months after ceasing the combined oral contraceptive. 
4. Progestogen-Only Pills (the mini-pill) 
The progestogen-only pill is recommended for women who experience side 
effects with the combined pills and for women who are lactating in whom the 
estrogen component of the combined pills would interfere with lactation21. 
The formulations used in the progestogen-only pill (mini-pill) in Australia are 
Levonorgestrel (3Omcg') and Norethisterone (35Omcg)ll. The mini-pill not only 
does not include estrogen, it also has a significantly lower progestogen dose than 
the combined pill. For that reason it has far fewer side effects but a higher 
pregnancy rate (3 per hundred women years23). In particular, the more dramatic 
pharmacological effects and probable harmful side effects associated with estrogen 
do not occur24. The scientific data suggests that the progestogen-only pill does not 
prevent ovulation in more than half of the women who use it. The range would 
seem to vary between 67% and 81 % of cases in which ovulation failed to be 
suppressed when the progesterone-only pill was used in women who had been 
normally ovulating25. 
The progestogen-only pill therefore depends largely on the other two factors: 
the disruption of the cervical mucus function26 and the changes to the lining of the 
uterus27. It is not known precisely which is more likely. 
Significantly, the effect on the endometrium differs between the different 
progestogen preparations28. What significance this has for the sustained effect of 
the formulations and whether the endometrial factor is likely to be more or less 
significant than the cervical factor has not been established29• 
It should be borne in mind that our interest in which factor is significant is not 
reflected in the published research priorities. A computer search of the literature 
yielded no recent study that aimed to find out whether the progestogen-only pill 
was abortifacient or contraceptive. The priorities in the literature are efficacy in 
terms of preventing the development of pregnancy and on the side-effects for 
women. The concentration at the moment is on pill usage in relation to cancer, 
cardio-vascular disease, drug interaction, metabolic disorders and some other 
diseases. Some progestogen-only formulations may be administered as an intra-
nasal spray rather than as a pill. The pharmacological effects would be much the 
same.30 
5. Triphasic and Biphasic Pills 
These are combined estrogen and progesterone formulations, but with the 
dosages of each varying through the month. Their purpose is to mimic more 
closely the normal cycle. With the ordinary combined pills, the same combined 
dosage is taken for 21 days of the cycle with inert tablets being taken for the rest 
(approx 7 dayS)31. A menstrual bleed occurs, but because the endometrial 
development has been so altered it is often a much lighter, less significant bleed32. 
The triphasic pills generally have a consistent level of estrogen at a relatively low 
dose, but they vary in the amount of progestogen. Some (such as Triphasil, 
Triquilar, Trifeme and Logynon ED) use Levonorgestrel with 50mcg in the first 
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six days, 75 mcg in the next five days and 125 mcg in the next 10 days. Thus the 
progestogen level gradually increases. Others (such as Synphasic) use 
Norethisterone with 500meg for the first seven days, lOOOmcg for the next nine 
days and 500 meg for the next five days33. 
With the lower dose of estrogen, it is more likely that ovulation is not always 
suppressed or disrupted and the cervical and endometrial factors become 
significant. A recent review of seven of the low dose combined pills showed that on 
ultrasound examination and serum hormone estimations ovarian suppression 
occurred in only 50% of cycles.34 The efficacy in terms of preventing pregnancy 
remained high with tablet related pregnancy, as distinct from patient error 
pregnancy, remaining at less than one per hundred women years.3S In those 
circumstances the endometrial and cervical factors are essential for the prevention 
of the development of pregnancy. 
The different levels of progestogen used at the different stages of the cycle are 
also significant in regard to which effect is more dominant, the contraceptive effect 
on the cervix or the abortifacient effect on the endometrium.36 A constant level of 
progrestogen would be needed to maintain the cervical factor. In the formulations 
in which the level of progestogen wanes significantly during the day, it would be 
much more likely that the endometrial (abortifacient) factor would be preventing 
pregnancy. 
The biphasic pills (such as biphasil and sequilar ED) use a constant 50mcg of 
ethinyloestradiol but vary the levonorgestrel from 50mcg in the first eleven days 
and 125mcg in the next ten days3? Hence, the estrogen level is high and most likely 
prevents ovulation. The cervical mucus and endometrial effects of the 
progestogen, although a back-up in case ovulation suppression fails, are thus 
probably not so significant in those formulations. 
6. Tricyclic Pills 
Athletes competing at sporting events, women marrying and wanting the 
wedding night free of menstruation, women undergoing academic examination 
and women simply not wanting the inconvenience of monthly cycles may choose 
to extend the twenty-one days of pill taking. Tricyclic pills extend the menstrual 
cycle to three months. 
The combined pill mainly suppresses ovulation and also has the back-up effects 
on the endometrium and the cervix. The woman experiences something like 
menstruation only after she stops taking the pill. The choice to use a standard 
twenty-one days of pill-taking followed by seven days of an inert pill establishes a 
regular twenty-eight day cycle. The manufacturers choose to do it that way, 
mimicking the normal menstrual cycle. However, shorter or longer periods may 
be chosen by varying the period that the combined pill is taken.38 Presumably the 
three actions of the combined pill remain the same in these long cycles but whether 
the actions on each of the target organs are more or less severe is seemingly not 
known. -
7. Post-CoitaI Oral Contraceptive Use 
In Australia, the practice of using combined the estrogen-progestogen pill in 
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high dosage as a morning-after pill is becoming more common. One of the high 
dose pills is used. Two pills are taken immediately and two more are taken twelve 
hours later. The result is a very high estrogen and progestogen peak followed soon 
after by a heavy bleed. The probable mechanism is abortifacient. It is possible that 
ovulation is suppressed depending on when the medication is taken in the cycle. 
The stage of the cycle and the time between intercourse and taking the pills would 
obviously be crucial in determining whether it is the contraceptive effect that 
works prior to the abortifacient effect and hence prevents fertilization39. 
General practitioners report that the demand for the morning-after pill has 
increased markedly in the last few years, probably as a result of condom 
promotion in relation to sexually transmissible diseases. It is common for teenagers 
to ask for the morning-after pill. It appears that, in the knowledge that the 
morning-after pill will resolve the problem, they may not take other precautions. 
Often they are accompanied to the doctor by their mothers! More women seemed 
to be depending on condoms in conjunction with the morning-after pill in the 
event of condom breakage or leakage. In actual human use, as distinct from 
laboratory testing, breakage rates in condoms that meet WHO laboratory test 
standards are between 7-13%40. Hence the demand for so-called "post-coital 
contraception", that is, abortifacients, is significant. 
8. Fonnulations Other than Estrogen-Progestogen Pills 
The major trend in fertility control seems to be toward the development of 
abortifacients. The new methods are sought as replacements for the intra-uterine 
device and the contraceptive pill. Intra-uterine devices are out of favour because of 
their reputed association with pelvic inflammatory disease. The contraceptive pill 
is contra-indicated now for women who smoke and there are reservations about its 
use in women over thirty-five. In addition, the tedium of a daily dose and disquiet 
about its side-effects have led to the search for alternatives to the contraceptive pill. 
Some attempts have been made to improve barrier methods but the major 
candidates for the future of medical control of fertility seem to be the anti-
progesterones, anti-estrogens, vaccines, inhibin, synthetic GnRH (Gonadotrophin 
Releasing Hormones), and monthly injections or implants. 
9. Antiprogesterones 
The so-called "abortion pill"41 RU486 (mifepristone) has been the centre of 
some controversy. Apart from the fact that RU486 causes abortions, pro-lifers 
have been concerned that the pill could be used on a regular basis; that it would be 
self-administered and would thus allow abortions to be achieved easily in the 
privacy and secrecy ofthe woman's home; and that the language used to describe it 
hides the fact that it is abortifacient. The new word "contragestive" is frequently 
used42. 
RU486 is being heavily promoted by the population control and pro-abortion 
lobbies and it is likely to gain widespread acceptance for use after pregnancy has 
been confirmed, as an alternative to surgical abortion, and possibly earlier as an 
immediate post-coital treatment. RU486 is now being trialled in Australia both in 
low dose as an immediate post-coital treatment, and later when the pregnancy is 
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known to have been established43• The trial in Australia is a part of a WHO 
international multi-centre trial. 
Some prcrabortionists have supported the agent as a much easier way of procuring 
an abortion than the surgical procedures involving curettage or vacuum aspiration.44• 
Some have claimed that it could be used without a pregnancy test when pregnancy is 
a possibility and menses are delayed. It has been argued that this would avoid the 
problems of guilt, and other psychological sequelae in relation to abortion: the 
woman would not know whether she had been pregnant. 
RU486 is a progesterone antagonist. It acts to inhibit the function of progesterone 
at the receptor level in the endometrium and other organs that respond to 
progesterone. In plain language that means that RU486 makes progesterone 
ineffective. Progesterone is essential for maintaining the lining of the uterus during 
pregnancy. Within a few days of administering RU486 after pregnancy has been 
established, the lining of the uterus sheds, taking with it the embryo or fetus if the 
woman is pregnant's. 
Administered immediately after coitus before pregnancy can be confirmed it 
would also seem to prevent nidation but the mechanism is uncertain. In the latter 
case, according to the plain language statements46 of the Australian trials, 
menstruation is usually delayed47. If administered very early after pregnancy has been 
established, the woman would experience an early abortion as a very heavy period48• 
RU486, used on its own, after pregnancy has been established, procures an early 
abortion in approximately 85% of cases49. However if used in conjunction with other 
agents the success rate may be as high as 95-100%50. RU486 can also be used 
effectively in the secondSI and third trimestersS2• If the current trial using RU486 
immediately after coitus is successful, then is likely to be used frequently as a back-up 
following barrier method failureS3• At first it was claimed that RU486 might be used 
to regularize cycles and prevent pregnancyS4, but uncertainty about the prolonged 
effects and dosages needed have led to the conclusion that this would not be 
appropriate5s. In addition the menses which follow the taking of RU486 are heavy 
and prolongedS6• The agent is thus not likely to be particularly appealing as a 
once-a-month "contraceptive". 
One of the problems inhibiting the use of R U486 as a "menstrual regulator" is that 
its effect is to block the function of progesterone. The rise in progesterone, on which 
so much depends, does not occur until the latter part of the cycle. This meant that, at 
first, it was held that if used too early in the cycle, the effectiveness of RU486 would 
be reduced. It was thought not to be effective in the absence ofluteal phase levels of 
progesteroneS7• The current WHO trial which Australia is participating in will prove 
or disprove that hypothesis. If the WHO trial is successful, RU486 might even gain 
approval as a self-administered home abortion pill. However the research and the 
manufacturers currently hold that it should only be used under close medical 
supervisionS8. The major reason for this is that there is usually heavy, prolonged 
bleeding which may endanger the woman's healths9. Follow-up treatments such as 
blood transfusion and curettage may be indicated in a small percentage of cru;es6O. 
The action of RU486 in inhibiting the effect of progesterone on the lining of the 
uterus is not the only direct effect. Some studies have shown that RU486 directly 
inhibits placental hormone secretion, having a direct effect on the embry061. Thus 
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RU486 not only brings about an abortion by affecting the lining of the uterus, it 
may also directly damage the embryo. The latter would be particularly relevant in 
the event that a woman chose not to have curettage after RU486 failed to procure 
an abortion. A complex range oflegal and ethical issues would arise in that event. 
If a woman had been ambivalent in the first instance, one could well imagine her 
deciding not to go further in the event of RU486 failure. Her rights and the medical 
and pharmaceutical liabilities would provoke conflict in such circumstances. The 
damage done to the embryo, and subsequently the child born at a later stage, 
would be an issue which the courts and the community would have to heed. 
The medical literature also contains the information that while the hormonal 
functions of the woman return to normal after R U486 has been used, there may be 
lasting effects on the tissues of the uterus and cervix. One study shows that cell 
dynamics which depend on a continuity of progresterone will be irreversibly 
disrupted62• The long term effects and the potential for serious adverse reactions 
are not yet known. The literature claims that it is safe, but only time will tell. The 
effects of hormonal treatments of this kind can be insidious and may only appear 
much later as was the case with the early high dose contraceptive pill, with some 
fertility drugs, and with some morning sickness therapies. 
RU486 can readily cross the blood-follicle barrier of human pre-ovulatory 
follicles. RU486 and its metabolites have been found in the egg-follicles in the 
ovaries of women undergoing sterilization to whom RU486 had been 
administered thirty-four hours earlier63• A question must therefore arise about the 
potential for damage to the ovaries and the egg follicles and the risk to any children 
subsequently conceived by a woman who has undergone RU486 therapy. 
RU486 does have some uses other than inducing abortion. Research has been 
done on it as a therapy following fetal death. Research has also been done on 
RU486 as an aid to ripening the cervix thus facilitating surgical abortion64• The 
agent may also be of therapeutic value in the treatment of breast cancer65. 
There is a very real danger that RU486 might be approved for prescription in 
Australia. Probably the conditions for its approved use would require that it be 
administered under close medical supervision. However, medical practitioners 
who are passionately in favour of private abortions might well interpret "close 
medical supervision" liberally and, at risk to their patients, prescribe RU486 in 
such a way as to allow it to be used as a home abortion pill. Once in the hands of 
unqualified personnel RU486 might then be adapted for regular use after menses 
delay in spite of that use being contra-indicated. 
10. Anti-estrogens 
A new development not yet reported to have been applied to humans is the 
development of anti-estrogens. A substance currently called CDRI-85/287 has 
been developed which interacts with the estrogen receptors thus blocking estrogen 
function in the same way that RU486 blocks progestrone function66• Estrogen is 
thought to have an essential role to play in the healthy functions of the cervix, the 
cervical mucus and sperm transport, in maintaining the corpus luteum, in ovum 
transport, and in the functions of the endometrium67• An anti-estrogen thus would 
be likely to disrupt healthy reproductive function. CDRI-85/287 has been shown 
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to affect implantation by causing changes to the rat uterus68. There are other 
similar developments such as the anti-estrogens ICI-182780 and nylestriol which 
have also been shown to inhibit implantation69• 
11. Contraceptive and Abortifacient Vaccines 
The immune system may be utilized in a number of ways in order to render a 
couple infertile. In layperson's terms, the immune system works by identifying a 
foreign body, then attacking it. Immunity develops normally by exposure to 
foreign bodies and the immune system learning to recognize them. Thus, for 
instance, a virus may infect a person, the immune system eventually recognizes it, 
targets it and then destroys it. In that process the immune system will have 
recorded the event and from then on retains the means of rapidly recognizing the 
virus. Future exposure to the virus results in an immediate attack response thus 
preventing the development of infection and illness. 
Two ways in which the contraceptive vaccines are likely to function are by 
producing a foreign body recognition of a man's sperm by his own immune 
system, or by producing a foreign body recognition of a man's sperm by his wife's 
immune system. The fertilizing capacity of the sperm is affected by the immune 
system and the system's response to the sperm may occur at many sites.70 For 
instance the anti-bodies may affect the sperm in the cervical mucus or at the site of 
sperm being absorbed in the ovum's zona pellucida.71 A further contraceptive 
possibility arises in relation to producing an immune response to ova72. 
The new ethical issues which arise in relation to the developments of 
contraceptive vaccines are to do with the risks for harm. The men and women who 
are subject to the experiments run the risk of developing an auto-immune disease. 
That is to say, the antibodies created may not be specific enough in targeting sperm 
or ova, and other tissues may be attacked. However, if animal studies show that 
these risks are minimal then the question of risk taking is only a matter of gaining 
informed consent to experiments. A much more complex issue would arise in 
relation to the risk of conception occuring and a child developing who had been 
damaged by experiments with vaccines against the sperm or ova from which he or 
she was conceived. 
A further use of the immune system, and a much more likely use, is the 
development of antibodies which inactivate key reproductive hormones necessary 
for the maintenance of a pregnancy. Anti-bodies to human chorionic 
gonadotrophin have been developed73. The latter has already been achieved in 
primates and is now being tried in women74. Such vaccines are abortifacient in that 
they act against the placenta and hence destroy the pregnancy. 
A major problem in relation to the abortifacient vaccine is that it is often 
described as contraceptive when there is little doubt that it is abortifacient. The 
effect is on the hormone produced by the chorion and the chorion does not exist 
prior to the formation of an embryo. The chorionic cells are not established until 
implantation is under way7S. 
12. Inhibin 
Inhibin is a naturally-occurring hormone identified by a Melbourne group of 
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scientists. It is thought to have a function as a messenger informing the 
hypothalamus in the brain about the status of development of ova or sperm. It may 
have a use in suppressing LH and FSH production thus potentially preventing 
ovulation.76 
13. Implants and Monthly Contraceptives 
Contraceptives that are injectable once a month and contraceptive implants 
ha ve been developed. 
Narp/ant is a subdermal slow release levonorgestrel implant which acts as a long 
term progestogen "contraceptive". A major function it has is to alter the 
endometrium thus preventing implantation77, but it also alters the cervical mucus 
and sometimes prevents ovulation78• 
eyclajem and Mesigyna (containing medroxyprogesterone acetate) are once-a-
month injectable "contraceptives" releasing both estrogen and progestogen79. 
From the literature it is not clear what levels of the two hormones are maintained 
throughout the month, and that makes it difficult to assess what is the predominant 
action: suppression of ovulation, changes to the cervical mucus or endometrial 
changes. Moral assessment might assume a similar action as that of the combined 
pill - probable suppression of ovulation and cervical mucus changes inhibiting 
fertilization, with the endometrial changes providing abortifacient back-up. 
However, the monthly injection is likely to provide a diminishing level of the 
hormones as the month progreses. It is probable that it depends more on being 
abortifacient than the daily oral contraceptives. 
It is thought that formulations containing medroxyprogesterone acetate may 
cause very severe lasting damage to the endometrium, even a condition called 
Asherman's syndrome when the woman may ovulate without menstruation. 
Asherman's syndrome can also occur after a radical destruction of the 
endometrium in the performance of a surgical abortion, and it can also occur as a 
congenital under-development of the uterus.80 
14. GnRH 
Gonadotrophin releasing hormone (GnRH) has an effect on the pituitary gland, 
the ovary and the testis. In men it inhibits the formation of sperm. GnRH is 
normally produced by the hypothalamus and works on the pituitary gland to 
trigger the production ofFSH and LH. The synthetic variety is more potent8l , One 
established effect of using a synthetic GnRH is in fact to block the action of 
estradiol82. The latter may have some use in altering cervical mucus function, 
suppressing ovulation and changing the endometrium. 
15. Hormone Releasing IUDs 
A further development is that of intra-uterine contraceptive devices (IUDs) 
which release progesterone. The effect would probably be to enhance the effect of 
the IUD on the lining of the uterus causing changes that prevent implantation.83 
16. Some Moral Consequences of the Trend Toward Abortifacients 
16.1 The Objective Problem 
The development of the moral tradition in regard to contraception has 
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presumed that contraception was, in fact, contraception. It now appears that many 
if not all of the pharmacological contraceptives are at least in part abortifacient, 
and the newer preparations under development tend to be entirely abortifacient, 
notwithstanding that they are promoted as contraceptives. 
This raises serious questions not only for the moral tradition but also for Church 
discipline. The Code of Canon law holds that a person who actually procures an 
abortion incurs a {atae sententiae excommunication (Canon 1398) and abortion is 
defined by the Pontifical Commission for the Authentic Interpretation of Canon 
Law as any method used to terminate a human life from the moment of 
conception until birth. 
Objectively, and assuming that one should always favor human life, the 
abortifacient component of oral contraceptives should result in them being 
regarded as abortifacient and assessed that way. That is, assessed as involving not 
only the wrong of contraception but the even more serious wrong of procuring an 
abortion. In the higher-dose combined pills that risk is relatively small but not 
assuredly so small that it is morally insignificant. Further it is a matter of risking 
human life which makes even a relatively small risk a serious matter. 
The moral assessment of the use of oral contraceptives for other medical 
purposes such as the management of hormonal imbalance, dysmenorrhoea and 
acne, must also change now that it is clear that the formulations are at least in part 
abortifacient. It is a question both of justice and proportionality. Significantly 
risking the life of a new human being is a disproportionate consequence of such 
treatments in a woman who is sexually active. The use of the estrogen-
progesterone contraceptive formulations for non-contraceptive purposes should 
be restricted to women who are not sexually active or are known to be otherwise 
incapable of conceiving. This would not, of course, preclude the use of hormone 
supplements for the purposes of treating infertility where the aim is to restore 
reproductive health so as to achieve pregnancy, provided that they were not used 
in doses that diminished the chances of a zygote implanting. 
Pastorally there are several matters to address in response to the information 
that oral contraceptives are at least partly abortifacient. The problem IS 
experienced differently by: 
* women and their partners using contraceptive-abortifacient formulations, 
* the doctors who prescribe the formulations, 
* the pharmacists filling prescriptions, 
* the manufacturers and researchers, and 
* the legislators and public policy-makers. 
* the Church 
16.2 Women Taking "Contraceptives" 
A major factor in the moral question in regard to women using pharmaceutical 
contraceptives is whether the abortifacient effect can be considered to be intended 
by them. Advice about the effects of oral contraceptives are provided to women 
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with packets of the pill. The high dose combined pills which are most likely to 
suppress ovulation and are thus least likely to have an abortifacient effect because 
fertilization would not usually occur, still carry a message to users, such as the 
following: 
The hormonal components [ . . . the preparation is named ... ) inhibit ovulation by 
suppressing gonadotrophin release. Secondary mechanisms which may contribute to the 
effectiveness of[ ... the preparation .. . J as a contraceptive include changes in the cervical 
mucus (which increase the difficulty of sperm penetration) and changes in the 
endometrium (which reduce the likelihood of implantation). 
Users are therefore informed of the anti-implantation effect but they may not 
understand that that is, in reality, an abortifacient effect. This does have a bearing 
on whether the pill is taken in good faith (in respect to taking an abortifacient) as a 
contraceptive and not as an abortifacient. 
Often, anti-implantation effects would seem not to be regarded as morally the 
same as abortion. The Congregation for the Doctrine of the Faith's teaching in 
198784 that the zygote (the cell formed by the fusion of the gametes) is to be given 
the respect due to the human person is not universally held even amongst 
theologians and that dissension, uncertainty or ignorance affects laypeople. 
Given that there is loss or possible loss of life involved in taking the oral 
contraceptive, women should be warned that that is the case and the moral 
conclusions drawn as a matter of pastoral guidance. 
Further, this may be treated as a matter of proportionality in that the intention 
of an informed woman (that is, one who knows of the possibility of an 
abortifacient effect) in taking an oral contraceptive may be to take a contraceptive 
and the abortifacient effect may simply be thought of as an unfortunate side effect. 
However, it is a question of loss of life and the proportionality conditions of the 
doctrine of double effect would have a bearing on the moral assessment even 
though the intention may be judged to be good in respect of not directly choosing 
abortion (but not, of course, in regard to contraception). There is a grave danger 
that the induced loss of early human life is being treated with indifference. In fact it 
is a matter of the utmost gravity. 
It has been argued by the Bishops of England and Wales that such a risk could 
be legitimately taken in the circumstances of rape85. That is to say, the Bishops 
accepted that contraception might be attempted after rape, and in an otherwise 
detailed treatment of the issue, left unanswered the question of the moral 
acceptability of the fact, acknowledged by them, that such contraceptive attempts 
might also be abortifacient in the circumstances of blind administration in which it 
was not known whether ovulation and possible fertilization had occurred. 
This matter needs clarification. What is appropriate management in the 
circumstances of rape? Is the self-defence argument in favor of attempting post-
coital contraception acceptable in the extreme case of rape when there are good 
grounds for believing that ovulation has not yet occurred? If so, is it permissible to 
attempt contraception in circumstances in which fertilization may not be 
prevented or may have already occurred and an abortifacient effect may be the 
result? 
A certain amount of risk-taking is obviously permissible in life. Every time we 
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travel by automobile we risk human lives. The question is one of the level of risk. If 
those risks were increased, at some point they would become unconscionable. 
That is to say they become disproportionate. The same must be said of the risk of a 
contraceptive-abortifacient in the circumstances of rape. At some point the risk of 
losing a life rather than preventing the generation of a life becomes 
disproportionate. 
It is important to stress that this question only arises in the circumstances of rape. 
One could not consider such ajustification in the ordinary circumstances of freely 
chosen acts, first because of the wrong of contraception, and second because 
contraception is not necessary for family planning. The ovulation awareness 
methods provide a viable and satisfactory ( not to mention healthier and morally 
acceptable) alternative. 
The significance of this discussion however is that the increasing likelihood of 
the contraceptive formulations being in fact abortifacient further vitiates such acts, 
adding an even more serious dimension - significant risk to human life. 
16.3 Prescribers 
Although women using the contraceptive-abortifacient formulations may be 
ignorant of the abortifacient risks, the same should not be the case for prescribers. 
Women using contraceptives might simply trust the advice given that what has 
been prescribed is in fact a contraceptive. But a medical practitioner should know 
more about the preparations. 
It is sometimes argued that the role of a medical practitioner in prescribing 
contraceptives is merely material co-operation and that the decision to contraceive 
is that ofthe patient rather than the practitioner. To the contrary, the reality is that 
the medical practitioner is a party not merely materially to the evil, but to the 
decision itself. It is the practitioner who puts the options to the woman. It is the 
practitioner who writes the prescription instructing the pharmacist. It is therefore a 
matter of conscience for the practitioner in regard to the wrong of contraception. 
Now that it is clear that the contraceptive formulations carry a significant risk of 
loss of life, the matter of prescribing them assumes an even more serious dimension 
for the prescribers. They not only participate formally in contraception, they also 
share direct responsibility for risking human life. 
There is a climate of wreckless indifference in regard to human life, particularly 
nascent human life, which medical practitioners should seek to resist and to 
challenge, 
16.4 Hospitals 
Much of what is said about prescribers also applies to hospitals. It really 
depends on the nature of the hospital's co-operation, the legal authority it has 
over prescribers within the hospital, and the extent to which such matters can 
be made the subject of formal policy and decisions by the hospital. 
It is worth noting that in 1971 the United States Catholic Conference drew 
a distinction in this respect, reportedly based on advice from the 
Congregation for the Doctrine of the Faith, between abortion and 
sterilization . The USCC held that it was sometimes permissible 
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for hospitals to remotely materially (but not formally) cooperate in sterilization 
but never in abortion.86 
The difference of course is that abortion involves matters of justice in regard to 
the unborn child. The same matters now are involved in the trend toward 
abortifacients in the pharmacological methods of birth control. 
Catholic hospitals exist to give practical healing witness to the teachings of 
Christ and of His Church. They, more than any other institutions, must have 
hospital policies and staff development policies which are in accord with an ethos 
of respect for human life and dignity. This matter of the developments in regard to 
contraceptive-abortifacients provides a serious cultural challenge to the reason for 
the existence of Catholic health care institutions, particularly those providing 
services in obstetrics and gynecology. 
16.5 Pharmacists 
The situation of pharmacists has always been a complex one. They are 
professionally trained and registered and expected to give advice about their 
preparations. However, in Australia they cannot generate or modify prescriptions 
without medical authorization. Contraceptive formulations are only available by 
medical prescription. It is an offence to sell or supply a prescription medication 
without a doctor's prescription. Pharmacists may, of course, be self-employed or 
be employed by hospitals or companies and that does affect the degree of freedom 
to refuse to fill a doctor's prescription on conscientious grounds. 
Generally it has been accepted, as a matter of theological opinion, that 
pharmacists materially, but not formally, co-operate when supplying contraceptives 
on a doctor's prescription. They are not a formal part of the evil and the oral 
contraceptives sometimes have medical uses other than contraception. However 
the principles of co-operation do require that the co-operation not be an injustice. 
The fact that the contraceptive formulations are significantly abortifacient changes 
the moral assessment. There is a grave matter of injustice to the human being, at 
the zygote stage of his or her development, in supplying formulations which put 
the life at risk. 
For that reason, this review of the medical literature and the conclusion reached 
that oral contraceptives at least risk being abortifacient has led me to change the 
view I previously held in regard to advising pharmacists. I am now inclined to the 
view that pharmacists should not fill prescriptions for oral contraceptive-
abortifacients to customers who may be sexually active. 
16.6 Manufacturers and Researchers 
The trend toward developing so-called "contraceptive" formulations that tend 
to be entirely or in part abortifacient is most unfortunate. 
Those who conscientiously are engaged in the pharmaceutical industry, in 
marketing, research, development or production, have moral obligations to ensure 
that their product is a good product. That is, that it is unlikely to cause harm and is 
good for human persons. Manufacturers cannot be held to be morally responsible 
for all the ways in which a product may be applied. But they are responsible for 
identifying its recommended applications and warning about potential harm or misuse. 
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That a pharmaceutical may cause loss of a human life at any stage of 
development ought not be hidden behind euphemism or misleading terms. Such 
medications should contain clear warning to that effect. The worst part of the 
current dilemma is the fact that abortifacients have been accepted readily because 
they have been marketed as contraceptives only, something other than what they 
are. 
Researchers also co-operate in the development of such products and they owe 
a duty of care to the community in regard to the contribution their efforts make to 
the society. The contemporary concentration in contraceptive research on 
developing abortifacients and the failure to distinguish between contraceptive and 
abortifacient effects is a serious wrong. 
16.7 Public Policy 
The safety of human life is an essential concern of the State in its role as 
protector of the common good. The development, production, marketing, supply, 
prescription and use of abortifacients is a matter which public authorities have an 
obligation to seek to control. 
It is part of the duty of the public authority to ensure that the civil law is regulated 
according to the fundamental norms of the moral law in matters concerning human rights, 
human life and the institution ofthe family. Politicians must commit themselves, through 
their interventions upon public opinion, to securing in society the widest possible 
consensus on such essential points and to consolidating this consensus wherever it risks 
being weakened or is in danger of collapse.87 
16.8 The Church 
A major problem in regard to the development of contraceptives toward being 
abortifacient is the manner in which abortifacients have come to be accepted as 
contraceptives. The source of the problem is medical indifference to the 
destruction of nascent human life. From that indifference flows a failure to 
communicate to women the real nature of the treatments and hence an ignorance 
on the part of both women and the general community. 
As a defender of human life and human dignity it is of grave importance that 
once having recognized that source of the problem, the teaching resources of the 
Church be employed to address the deficiency. More than anything this is a matter 
of insisting that women are given full information about the effects of the 
contraceptives. 
The Church is often accused of being embryo-centric to the exclusion of the 
rights bf women and their free choice. Here, however, it is those who would 
threaten the lives of the innocent who are denying free choice to women by 
denying them relevant information needed to make decisions about family 
planning. This is not only injustice to the child in the womb, but an injustice to 
women. 
There is a need for clear teaching on abortifacients and the deceit involved,not 
only as a matter of respect for human life but also as a matter of the rights of 
women to know what they are doing to their own bodies and to the lives for whom 
their bodies are rendered hostile without the women's knowledge. 
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17. Contraceptive Failure 
Contraceptive failure with the oral contraceptives occurs both as a result of 
method failure and as a result of user error and interaction with other medications. 
From a pro-life perspective, the nature ofthe support and advice given to women 
in such instances is of great importance. This is particularly so when the use of a 
reasonably reliable method of contraception fails and the woman has no prior 
expectation of pregnancy. 
The method-related failures of oral contraceptives are given thus: 
The pregnancy rates in women using conventional combination oral contraceptives 
(containing 35 micrograms or more of ethinyloestradiol or 50 micrograms or more 
mestranol) is generally reported as less than I pregnancy per 100 woman-years of use. 
Slightly higher rates (somewhat more than I pregnancy per 100 woman-years of use) are 
reported for some combination products containing 35 micrograms or less of 
ethinyloestradiol, and rates of the order of 3 pregnancies per 100 woman years are 
reported for the progestogen-only oral contraceptives.88 
If you take into account that many woman become sexually active in their teens, 
their actual childbearing period is to be limited to two or three live births, and their 
naturally fertile life will extend over thirty years, then most women will wish to 
avoid pregnancy for twenty to twenty-five years. The chance of having an 
unexpected pregnancy at some time during their fertile years if they depend on the 
pill during the times that they do not want to be pregnant is thus 20-25% with the 
conventional preparations, more than 20-25% with the low dose combined pill 
and 60-75% with the progestogen-only pill, and that is without allowing for user 
failure such as missing pills, taking them at a different time of day, taking them 
with agents which have a known drug interaction with oral contraceptives, or 
having a stomach upset. 
The failure rate thus accounts for a significant proportion of unplanned 
pregnancies. Such pregnancies come as a complete surprise, particularly if they are 
entirely method-related. Many women think that the pill makes them immune to 
pregnancy, hence when it occurs in a woman taking the pill, it can be devastating. 
From a realistic pro-life perspective, permanent sterilization apart, willingness 
to engage in sexual intercourse should be premised upon a willingness to accept the 
possibility of pregnancy and the birth of a child. A pro-life view should thus link 
sexual intercourse with a willingness to form a family. That view is not shared by 
the Family Planning Associations. 
The chances of a pregnancy can be greatly reduced by oral contraceptives. The 
chances can also be limited to an equivalent extent by the timing of sexual 
intercourse so that it does not coincide with the fertile stage of the cycle. Possible 
fertile times can be identified readily by the presence of cervical mucus observed at 
the vulva on that day or the preceding three days. The World Health Organization 
figures89 indicate that the Billings Ovulation Method of observing mucus changes 
is more reliable than the mini-pill and about as reliable as the combined pills. The 
observation of the temperature rise that follows ovulation is also an indication of 
the fertile period having passed. Those natural methods can also be assisted, for 
women who find observation of the signs of fertility difficult, by the use of 
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hormonal testing which is now available in a Do-It-Yourself Kit. 
The disadvantage of the abstinence methods is that they do involve days of 
abstinence. The major advantages are that they do not involve the health risks and 
unpleasant side-effects of the oral contraceptives, do not carry the abortifacient 
risks of the oral contraceptives, foster a co-operative relationship between spouses 
in which responsibility for controlling fertility is shared, increase awareness of the 
changes in the woman's body, provide early warning of a variety of medical 
conditions, and provide information which assists couples who have difficulty 
conceiving. 
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